Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Feb 13;23(1):23.
doi: 10.1186/s12958-025-01349-4.

The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis

Affiliations
Meta-Analysis

The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis

Biyun Zhang et al. Reprod Biol Endocrinol. .

Abstract

Objective: To summarize evidence on the efficacy and safety of the levonorgestrel-releasing intrauterine system (LNG-IUS) in managing adenomyosis (AM), both as a monotherapy and in combination with other therapies.

Methods: We searched Medical Literature Analysis and Retrieval System On-Line: Medline, The Cochrane Library, Embase, SinoMed, China National Knowledge Infrastructure, and Wanfang from the inception to Aug 12, 2024 for articles using the LNG-IUS both alone and combined with other therapies in patients with AM. The primary outcome included dysmenorrhea, menstrual bleeding, uterine volume, endometrial thickness and quality of life. The secondary outcome was the assessment of adverse events. Data synthesis was conducted using random-effects model with significant heterogeneity (I2 > 50%), otherwise using fixed-effects model.

Results: The final analysis included 28 studies. Compared with etonogestrel, LNG-IUS was more effective in reducing uterine volume and associated with a lower risk of weight gain, but showed no significant difference in reducing dysmenorrhea and endometrial thickness. Comparing LNG-IUS with mifepristone, there was no significant difference in terms of quality of life. The combination of LNG-IUS with Gonadotropin-releasing hormone agonists (GnRH-a) was more effective than LNG-IUS alone, providing benefits in reducing dysmenorrhea (mean deviation, MD: -1.14), menstrual bleeding (MD: -11.94), uterine volume (MD: -30.39), endometrial thickness (MD: -0.89), and adverse events. The combination of LNG-IUS with surgical excision was more effective than surgical excision alone, providing benefits in reducing dysmenorrhea (MD: -1.49), menstrual bleeding (MD: -5.13) at 12 months, reducing uterine volume at 6 (MD: -9.23), 12 (MD: -16.53) and 24 (MD: -27.17) months. The combination of LNG-IUS with focused ultrasound ablation (FUA) was more effective than FUA alone, providing benefits in reducing dysmenorrhea (MD: -0.62), menstrual bleeding (MD: 0.17).

Conclusions: This study found no clear evidence to recommend single-drug therapy for improving pain and quality of life in AM management within 12 months. Combining LNG-IUS with GnRH-a is effective in alleviating pain, controlling heavy bleeding, reducing lesion volume, reducing the probability of expulsion and irregular bleeding. Postoperative LNG-IUS helps reduce long-term pain and bleeding. In combined FUA, LNG-IUS is effective for managing short-term pain and bleeding.

Trial registration: PROSPERO registration number: CRD42024578824.

Keywords: Adenomyosis; Efficiency; LNG-IUS; Safety; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA 2020 flowchart representing the study selection process
Fig. 2
Fig. 2
Forest plot of the pain score after LNG-IUS insertion or etonogestrel subcutaneous implantation
Fig. 3
Fig. 3
Forest plot of the uterus volume after LNG-IUS insertion or etonogestrel subcutaneous implantation
Fig. 4
Fig. 4
Forest plot of the endometrial thickness after LNG-IUS insertion or etonogestrel subcutaneous implantation
Fig. 5
Fig. 5
Forest plot of the adverse effects after LNG-IUS insertion or etonogestrel subcutaneous implantation
Fig. 6
Fig. 6
Forest plot of the quality of life after LNG-IUS insertion or mifepristone treatment at 6-month follow-up
Fig. 7
Fig. 7
Forest plot of the quality of life after LNG-IUS insertion or mifepristone treatment at 12-month follow-up
Fig. 8
Fig. 8
Forest plot of the pain score after GnRH-a + LNG-IUS or LNG-IUS only
Fig. 9
Fig. 9
Forest plot of the PBAC after GnRH-a + LNG-IUS or LNG-IUS only
Fig. 10
Fig. 10
Forest plot of the uterine volume after GnRH-a + LNG-IUS or LNG-IUS only
Fig. 11
Fig. 11
Forest plot of the endometrial thickness after GnRH-a + LNG-IUS or LNG-IUS only
Fig. 12
Fig. 12
Forest plot of the adverse effects after GnRH-a + LNG-IUS or LNG-IUS only
Fig. 13
Fig. 13
Forest plot of the pain score points after surgical excision + LNG-IUS insertion or surgical excision only
Fig. 14
Fig. 14
Forest plot of the PBAC after surgical excision + LNG-IUS or surgical excision only
Fig. 15
Fig. 15
Forest plot of the uterine volume after surgical excision + LNG-IUS or surgical excision only
Fig. 16
Fig. 16
Forest plot of the change in the pain score after FUA + LNG-IUS or FUA only
Fig. 17
Fig. 17
Forest plot of the effect of dysmenorrhea after FUA + LNG-IUS or FUA only
Fig. 18
Fig. 18
Forest plot of the change in the PBAC after FUA + LNG-IUS or FUA only

Similar articles

Cited by

References

    1. Leng J. Chinese experts’ consensus on diagnosis and treatment of adenomyosis. Chin J Obstet Gynecol. 2020;55:376–83. 10.3760/cma.j.cn112141-20200228-00150. - PubMed
    1. Xiong F, Li W, Rao X. Comparison of hysteroscopic electrotomy and curettagein the treatment of abnormal uterine bleeding caused byendometrial polyps. Contemp Med. 2021;27:88–90.
    1. Chinese Obstetricians and Gynecologists Association; Cooperative Group of Endometriosis, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Guideline for the diagnosis and treatment of endometriosis (third edition). Chin J Obstet Gynecol. 2021;56:812–24. 10.3760/cma.j.cn112141-20211018-00603.
    1. Gemzell-Danielsson K, Kubba A, Caetano C, Faustmann T, Lukkari-Lax E, Heikinheimo O. Thirty years of mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100:614–8. 10.1111/aogs.14110. - PMC - PubMed
    1. Dason ES, Chan C, Sobel M. Diagnosis and treatment of adenomyosis. CMAJ: Can Med Association J = J de L’Association Medicale Canadienne. 2021;193:E242. 10.1016/j.jogc.2023.04.008. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources